株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ベトナムの医薬品・医療産業(四半期更新レポート)

Vietnam Pharmaceuticals and Healthcare Report Q2 2017

発行 BMI Research 商品コード 179567
出版日 ページ情報 英文 105 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=112.34円で換算しております。
Back to Top
ベトナムの医薬品・医療産業(四半期更新レポート) Vietnam Pharmaceuticals and Healthcare Report Q2 2017
出版日: 2017年04月05日 ページ情報: 英文 105 Pages
担当者のコメント
このシリーズは、他にも調査対象国がございます。詳細はお問合せください。
概要

当レポートでは、ベトナムにおける製薬・医療産業の構造や最新動向について分析し、今後10年間の産業規模の動きを推計すると共に、業界の抱える課題(リスク)や将来的な収益機会(リワード)に関する評価、政府の政策・規制、マクロ経済環境、主要企業のプロファイルといった情報を盛り込んでお届けします。

BMIの見解

SWOT分析

産業予測

  • 医薬品市場の予測
  • 医療市場の予測
  • 処方薬市場の予測
  • 特許薬市場の予測
  • ジェネリック医薬品市場の予測
  • 一般用(OTC)医薬品市場の予測
  • 医薬品の対外貿易状況

産業のリスク/リワード・レーティング

  • アジア太平洋地域:リスク/リワード・レーティング
  • ベトナム:リスク/リワード・レーティング
    • リワード
    • リスク

規制について

  • 知的所有権の問題
  • 価格設定の体制
    • 医療費償還の体制

市場概況

  • 医療部門での資金調達
  • 研究開発(R&D)
  • 治験

競争環境

  • 研究開発指向型産業
  • 医薬品の流通
  • 医薬品の小売部門

企業プロファイル

人口動態予測

用語集

分析手法

  • 医薬品支出額の予測モデル
  • 医療費の予測モデル
  • 分析手法に関する注記
  • リスク/リワード・レーティングの手法
  • レーティングの概要
  • 指標のウェイト付け

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: 1748-2305

BMI View: Vietnam's ongoing epidemiological transition will see chronic conditions become the primary drivers of pharmaceutical demand. Among these, cardiovascular diseases will be a key therapeutic area, as its high prevalence remains supported by the entrenchment of a wide range of risk factors. Neoplastic treatments will also contribute significantly to the overall market, as well as efforts to improve cancer screening being rolled out across the country. While communicable diseases are on the decline in Vietnam, infectious diseases such as dengue will remain prevalent, and treatments targeting these areas will contribute to overall pharmaceutical sales.

Headline Expenditure Projections

  • Pharmaceuticals: VND105trn (USD4.7bn) in 2016 to VND119trn (USD5.2bn) in 2017; +13% in local currency terms and +10% in US dollar terms.
  • Healthcare: VND333trn (USD14bn) in 2016 to VND365trn (USD15bn) in 2017; +9.8% in local currency terms and +7.1% in US dollar terms.

Risk/Reward Index

In Q217 Vietnam's Pharmaceuticals Risk/Reward Index score remains unchanged at 48.3 out of a maximum of 100. Vietnam remains ranked 13th out of 20 countries monitored in the Asia Pacific region in terms of market attractiveness to pharmaceutical investors. Vietnam's score is driven by a relatively large market size (scoring 12.0 for this index component, above the regional average of 10.1) and robust sector value growth (scoring 9.6, above the regional average of 6.7), but is dragged down by low spending per capita on medicine (scoring 2.4, against the regional average of 3.8) and subdued patent respect (scoring 2.8, against the regional average of 3.3).

Table of Contents

BMI Industry View

  • Table: Headline Pharmaceuticals & Healthcare Forecasts (Vietnam 2015-2021)

SWOT

Industry Forecast

  • Pharmaceutical Market Forecast
    • Table: Pharmaceutical Sales, Historical Data And Forecasts (Vietnam 2013-2021)
  • Healthcare Market Forecast
    • Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Vietnam 2013-2021)
    • Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Vietnam 2013-2021)
    • Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Vietnam 2013-2021)
  • Prescription Drug Market Forecast
    • Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Vietnam 2013-2021)
  • Patented Drug Market Forecast
    • Table: Patented Drug Market Indicators, Historical Data And Forecasts (Vietnam 2013-2021)
  • Generic Drug Market Forecast
    • Table: Generic Drug Market Indicators, Historical Data And Forecasts (Vietnam 2013-2021)
  • OTC Medicine Market Forecast
    • Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Vietnam 2013-2021)
  • Pharmaceutical Trade Forecast
    • Table: Pharmaceutical Trade Data And Forecasts (Vietnam 2015-2021)
    • Table: Pharmaceutical Trade Data And Forecasts local currency (Vietnam 2015-2021)

Pharmaceuticals & Healthcare Risk/Reward Index

  • Asia Pacific Risk/Reward Index - Q2 2017
  • Vietnam Risk/Reward Index
    • Rewards
    • Risks

Regulatory Review

  • Intellectual Property Issues
    • Table: Special 301 Submission: Issues Raised For Vietnam
  • Pricing Regime
  • Reimbursement Regime

Market Overview

  • Healthcare Sector
    • Table: Healthcare Resources (Vietnam 2011-2016)
    • Table: Healthcare Personnel (Vietnam 2011-2016)
    • Table: Healthcare Activity (Vietnam 2011-2016)
  • Research & Development
    • Clinical Trials
    • Epidemiology

Competitive Landscape

  • Research-Based Industry
    • Table: Multinational Market Activity
  • Pharmaceutical Distribution
  • Pharmaceutical Retail Sector
    • Table: Key Aspects Of Good Pharmacy Practice In Developing Countries

Company Profile

  • DHG Pharmaceutical
  • GlaxoSmithKline
  • Sanofi
  • Traphaco Pharmaceutical
  • Vietnam Pharmaceutical Corporation (Vinapharm)

Demographic Forecast

  • Demographic Outlook
    • Table: Population Headline Indicators (Vietnam 1990-2025)
    • Table: Key Population Ratios (Vietnam 1990-2025)
    • Table: Urban/Rural Population & Life Expectancy (Vietnam 1990-2025)
    • Table: Population By Age Group (Vietnam 1990-2025)
    • Table: Population By Age Group % (Vietnam 1990-2025)

Glossary

Methodology

  • Pharmaceutical Expenditure Forecast Model
  • Healthcare Expenditure Forecast Model
  • Notes On Methodology
  • Risk/Reward Index Methodology
    • Table: Indicators - Rationale And Sources
Back to Top